Long term adherence to antiretroviral therapy in a South African cohort.
Loading...
Date
2018
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background
Current treatment of HIV requires life-long antiretroviral therapy (ART) to suppress HIV replication.
Adherence to medication is a critical component of treatment success, where ≥95% of doses, must be
taken to achieve and maintain undetectable viral loads which are essential for successful patient and
public health outcomes. Although South Africa recently introduced universal test and treat (UTT) and
supports the largest number of people living with HIV (PLWH) on treatment in the world, there is
limited data on long term adherence in our population.
Objective
The aim of this project was to retrospectively assess long term adherence in HIV infected patients on
ART for at least five years or longer in order to inform long term care.
Methodology
Long-term adherence to ART was retrospectively analysed in HIV infected, ART naïve patients, first
enrolled in a randomised controlled trial assessing tuberculosis (TB) and HIV treatment integration
(N=642) and subsequently followed post-trial in an observational cohort study (N=402) in Durban,
South Africa. Adherence was determined by assessing monthly or quarterly (depending on
appointment schedule) pharmacy pill counts for patients on ART for five years or longer.
Results
From the initial randomized control trial cohort of 642 patients, 270 met the inclusion criteria for this
analysis; 54.8% were female, median age was 34 years (IQR: 29-40) and median time on ART was 70
months (IQR: 64-78). Mean ART adherence was maintained at ≥ 95% for each year on ART and
93.9% of patients maintained viral suppression by the end of the follow up period. Pill count based
adherence estimates showed high sensitivity (95%; 95%CI: 91-98%) in predicting viral suppression
but poor specificity (9%; 95%CI: 0-41%) for predicting detectable viral loads at five years post-ART
initiation. However, half of all patients had at least one sub-optimal (<95%) pill count in the first six
months after ART initiation and <20% between the first and sixth year. Viral suppression was 87.4%
six months after ART initiation and increased thereafter, remaining >92% throughout follow-up. HIV
and TB co-treatment or switching to second line regimens with high pill burdens did not worsen
adherence. Mean adherence was >99% in stable patients provided with an extended 90-day ART
supply.
Conclusion
Our study found overall high adherence to ART in this South African cohort followed up over a
period of more than five years. Treatment outcomes were successful on both first and second line treatment. Pill count was not a good predictor of virologic failure in our study and viral load measurement should be used as the benchmark for monitoring treatment response as required by current guidelines. However, adherence during the initial six months after ART initiation has been shown to impact long term treatment outcomes, therefore, pill count may be used as a quick, simple measure of adherence to identify patients with early adherence challenges and provide the opportunity for timeous adherence interventions. Optimal long-term adherence with successful treatment outcomes are possible within a structured ART programme with close adherence monitoring.This adherence support approach and these findings are relevant in the era of UTT.
Description
Masters in Pharmacy (Pharmacy Practice). School of
Health Sciences, University of KwaZulu-Natal, Westville Campus, 2018.